Previous 10 | Next 10 |
2024-01-06 22:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the...
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in...
2023-11-28 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cullinan Oncology Inc. (CGEM) is expected to report $-0.91 for Q3 2023
2023-11-08 08:48:48 ET More on Cullinan Oncology Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data Cullinan Oncology (CGEM) Investor Presentation - Slideshow Seeking Alpha’s Quant Rating on Cullinan Oncology Historical earnings dat...
Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024 Initial CLN-619 clinical biomarker data support mechanism of action and demonstrate monotherapy clinic...
Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed mechanism of action and demonstrates that the observed monotherapy clinical activit...
2023-09-11 11:57:47 ET Summary Cullinan Oncology's stock remains below cash value despite positive phase 1 trial data for its second asset, CLN-619. The company's lead asset, Zipalertinib, has shown promising results in treating EGFRex20ins NSCLC, positioning it as a potential tre...
2023-08-10 12:11:29 ET Cullinan Oncology press release ( NASDAQ: CGEM ): Q2 GAAP EPS of -$0.82 beats by $0.15 . Cash and investment position of $512.1 million as of June 30, 2023 continues to provide runway into 2026 For further details see: Cullinan Oncology...
News, Short Squeeze, Breakout and More Instantly...
Cullinan Oncology Inc. Company Name:
CGEM Stock Symbol:
OTCMKTS Market:
Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Cullinan Therapeutics Inc. (CGEM) is expected to report $-0.9 for Q1 2024